Sarasin & Partners LLP Cuts Stake in Amgen Inc. $AMGN

Sarasin & Partners LLP lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 48.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 343,948 shares of the medical research company’s stock after selling 322,502 shares during the quarter. Amgen makes up approximately 1.5% of Sarasin & Partners LLP’s portfolio, making the stock its 24th largest holding. Sarasin & Partners LLP owned about 0.06% of Amgen worth $124,550,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in AMGN. Anfield Capital Management LLC increased its stake in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC lifted its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Tower View Wealth Management LLC grew its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares during the period. Manning & Napier Advisors LLC increased its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in Amgen in the fourth quarter worth $34,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported second-quarter revenue of $10.05 billion, up approximately 9.5% year over year, while adjusted EPS of $6.29 exceeded the roughly $5.62 analyst consensus. Growth across cardiovascular, bone-health, and rare-disease medicines helped offset pressure from older products facing biosimilar competition. Amgen second-quarter sales rise 9%, profit tops Street view
• Positive Sentiment: Management raised its 2026 outlook, with adjusted EPS guidance of $22.30 to $23.50 and revenue guidance of approximately $38.2 billion to $39.4 billion. The update reflects momentum across Amgen’s portfolio and continued progress in its late-stage pipeline. AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
• Positive Sentiment: Several firms raised their targets following the results. UBS lifted its target to $440 and TD Cowen to $452, while BMO, Oppenheimer, and Scotiabank set targets near $450 or higher; UBS and TD Cowen maintained bullish ratings. Amgen Price Target Raised to $440 at UBS
• Neutral Sentiment: Analyst sentiment remains divided. Citi maintained a Hold rating, while UBS retained Buy; other firms raised targets but kept Hold, Equal Weight, or Underperform ratings, suggesting some analysts believe the upgraded outlook is already reflected in the valuation. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Amgen abandoned an obesity-drug candidate, while pressure from biosimilars and weaker performance in some legacy franchises remains a headwind. Questions surrounding Tavneos clinical data add regulatory and reputational uncertainty. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Negative Sentiment: A reported patient-data breach has prompted a law-firm investigation into potential privacy claims, creating additional legal, operational, and reputational risk for Amgen. Amgen Data Breach Class Action Investigation

Amgen Price Performance

Amgen stock opened at $404.85 on Friday. The firm has a market capitalization of $218.50 billion, a P/E ratio of 25.16, a PEG ratio of 4.10 and a beta of 0.41. Amgen Inc. has a one year low of $269.77 and a one year high of $418.40. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.01. The business has a fifty day moving average price of $361.29 and a 200-day moving average price of $355.86.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the previous year, the company posted $6.02 EPS. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.47 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 70.15%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Royal Bank Of Canada upped their price target on Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday. Weiss Ratings lowered Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday, June 5th. Morgan Stanley upped their price objective on shares of Amgen from $333.00 to $351.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, Wells Fargo & Company increased their target price on shares of Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $367.93.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.